Aerie Pharmaceuticals price target raised to $36 from $27 at RBC Capital RBC Capital believes that Phase IIb results for Aerie's glaucoma treatment, Roclatan, lower the risks faced by the company. The firm says that the data would be good enough to support approval of the drug if the trial was a Phase III study. It keeps an Outperform rating on the shares.
Aerie Pharmaceuticals pullback a buying opportunity, says Brean Capital Brean Capital analyst Difei Yang views the recent pullback in shares of Aerie Pharmaceuticals as a buying opportunity. After speaking to clients and company management, Yang sees no potential issues to warrant the recent selloff. The analyst points out that the company has more than $150M in cash, enough to support operations until 2017, making a capital raise very unlikely. Yang has a Buy rating on Aerie with a $48 price target.